NGF leadership Dompé is a long-standing, independent biopharmaceutical company focused on nerve growth factor (NGF) and disease-modifying therapies for nervous system conditions, presenting opportunities in partnerships or co-development around NGF-driven programs and related ophthalmic, neurological, and pain indications.

Rare eye therapies Achieved first topical biologic approval for a rare neurotrophic eye disease, signalling experience in ophthalmology and a track record for bringing innovative eye care solutions to market, enabling pitches for further ophthalmic collaborations and access programs.

Global expansion Established North American presence with New York operations since 2014 and ongoing international development strategy, offering avenues for collaboration with US healthcare payers, distributors, and clinical trial sites to accelerate global access and commercialization.

Innovation ecosystem Strong integration of research, manufacturing, and commercialization with a science-driven, agile R&D model and collaborations (e.g., AI-enabled discovery platforms and Eurofins Discovery integration), creating opportunities for strategic partnerships, licensing, and platform-based programs.

Talent and partnerships Active focus on education, talent development, and leadership transitions, plus notable executive moves in the industry, suggesting potential for executive-level partnerships, advisory roles, and joint development or talent-based collaboration in high-need neuroscience and inflammation areas.